As potential strategies for the treatment of COVID-19, the pharmacological inhibition of TMPRSS2 or the bond between human recombinant soluble ACE2 and the receptor-binding domain of S-protein could significantly reduce infection by SARS-CoV-2 (34) (Figure 2A). The gene discussed is ACE2; the disease is infection.